GLIVEC extended median overall survival to almost 5 years1,2

In a clinical trial, median overall survival with GLIVEC was 57 months in advanced disease compared with 10 months prior to GLIVEC1,2*

Nearly 5-year overall survival (OS) with GLIVEC1,2

GLIVEC delivers significant clinical benefit to most patients with advanced KIT+ GIST1

  • Absence of progression is an excellent predictive marker of OS and progression-free survival (PFS) in advanced GIST5†
  • Patients showing nonprogression of disease by 6 months of treatment had the same outcomes as those who showed complete or partial response5†
Patients with KIT+ GIST achieving disease control with GLIVEC over a 5-year follow-up (N=147)1
  • The efficacy of GLIVEC was confirmed in a combined analysis of 1640 patients with unresectable or metastatic KIT+ GIST6
  • In a Phase 3 study of patients who interrupted therapy, 92% (24/26) who restarted GLIVEC after experiencing disease progression achieved disease control7,8‡

*10-month OS is from historical GIST controls from the European Organisation for Research and Treatment of Cancer database. According to Response Evaluation Criteria in Solid Tumors (RECIST). Disease control is defined as complete response, partial response, or stable disease.

References: 1. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625. 2. Verweij J, Casali PG, Zalcberg J, et al; for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134. 3. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2016. 4. Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd; 2014. 5. Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27(24):3969-3974. 6. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247-1253. 7. Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232. 8. Blay J-Y, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113.